A A AText only | Accessibility | Privacy and cookies

Browse site A to Z

Search results

Go To Simple Search

You could also try: swelling (247), rise (125), improvement (317), growth (369), extension (76)

Pembrolizumab_400mg skin

Description
Chemotherapy Protocol SKIN CANCER Pembrolizumab (400mg) Regimen • Skin – Pembrolizumab (400mg) Indication • Pembrolizumab is recommended; - as an optio
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/Pembrolizumab-400mg.pdf

Pembrolizumab_200mg skin

Description
Regimen Chemotherapy Protocol SKIN CANCER Pembrolizumab (200mg) • Skin – Pembrolizumab (200mg) Indication • Pembrolizumab is recommended; - as an optio
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/Pembrolizumab-200mg.pdf

Pembrolizumab Ver 1 skin

Description
Chemotherapy Protocol SKIN CANCER Pembrolizumab Pembrolizumab is currently available on a compassionate use basis only – not yet licensed in the UK Reg
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/SkinPembrolizumabVer1.pdf

Nivolumab Ver 1.1 skin

Description
Chemotherapy Protocol SKIN CANCER Nivolumab This regimen may require funding. Regimen Skin – Nivolumab Indication The treatment
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/NivolumabVer1.1.pdf

Nivolumab 480mg skin

Description
Chemotherapy Protocol SKIN CANCER Nivolumab (480mg-28 days) Regimen • Skin – Nivolumab (480mg-28 days) Indication • Nivolumab is recommended, within it
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/Nivolumab-480mg.pdf

Nivolumab 240mg skin

Description
Chemotherapy Protocol SKIN CANCER Nivolumab (240mg-14 days) Regimen • Skin – Nivolumab (240mg-14 days) Indication • Nivolumab is recommended, within it
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/Nivolumab-240mg.pdf

Ipilimumab-Nivolumab

Description
Chemotherapy Protocol SKIN CANCER IPILIMUMAB (3mg/kg)-NIVOLUMAB (1mg/kg) Regimen • Skin – Ipilimumab (3mg/kg)-Nivolumab (1mg/k
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/Ipilimumab-Nivolumab.pdf

Pembrolizumab (200mg)

Description
Regimen Chemotherapy Protocol HEAD AND NECK CANCER Pembrolizumab (200mg) • Head and Neck – Pembrolizumab (200mg) Indication • Pembrolizumab is recommen
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Headandneckcancer/Pembrolizumab-200mg.pdf

Nivolumab_240mg

Description
Chemotherapy Protocol HEAD AND NECK CANCER Nivolumab (240mg-14 days) Regimen • Head and Neck – Nivolumab (240mg-14 days) Indication • The treatment of
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Headandneckcancer/Nivolumab-240mg.pdf

Nivolumab

Description
Chemotherapy Protocol HEAD AND NECK CANCER Nivolumab Regimen • Head and Neck – Nivolumab Indication • The treatment of recurrent or metastatic squamous
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Headandneckcancer/Nivolumab.pdf
21 to 30 of 41
Previous 1 2 3 4 5 Next